MedTrace Logo

A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol

NCT05127304 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11316

Last updated 2023-11-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate disease-related and all-cause burden and clinical outcomes of interest following initiation of chronic obstructive lung disease (COPD) maintenance therapy with Tiotropium Bromide/Olodaterol (TIO/OLO) or Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Trelegy Ellipta

Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol

DEVICE

Stiolto Respimat

Stiolto Respimat with Tiotropium Bromide/Olodaterol

DRUG

Furoate/Umeclidinium/Vilanterol

Furoate/Umeclidinium/Vilanterol

DRUG

Tiotropium Bromide/Olodaterol

Tiotropium Bromide/Olodaterol

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-26
Primary Completion
2022-02-03
Completion
2022-02-03
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127304 on ClinicalTrials.gov